An interventional study of Standard Non-Invasive Mechanical Servo Ventilation and Neurally-Adjusted Ventilatory Assistance (NAVA) Non-Invasive Mechanical Servo Ventilation in Bronchiolitis, sponsored by Montefiore Medical Center. Terminated at 1 site in United States. Open to participants aged 0 Years to 2 Years. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Montefiore Medical Center · Not applicable, Interventional, and Treatment
Challenges associated with accrual of the eligible patient population.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Bronchiolitis with a site in United States — 4 open to participants now, 7 under way, 1 of them phase 3. Bronchiolitis · United States.
Among the 65 studies in Bronchiolitis with a site in United States, this one is the 41st largest by enrollment of the 49 interventional ones that give a count, is one of 3 that started in 2023, is one of 33 with no phase, and was the 60th registered.
289 studies on the registry are indexed under Bronchiolitis; 51 are open to participants now.
Browse Bronchiolitis studies →4 of the 65 studies in Bronchiolitis with a site in United States are open now. Recruiting first, the newest first:
Seattle Children's Hospital · Sites in United States, Canada
Ages 0 mo–24 mo
Deciphera Pharmaceuticals, LLC · Sites in United States
Ages 18+
Nemours Children's Clinic · Sites in United States
Ages 3 mo–24 mo
National Jewish Health · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 26 Bronchiolitis studies recruiting now, 4 (15%) set no upper age limit and 21 (81%) stop at 75 or younger; 23 take children under 18; none take healthy volunteers.
This study: 0 Years to 2 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 5 · Phase 4 5
First in 1999; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 96 across 195 interventional studies indexed under Bronchiolitis.
Median enrollment 72 across the 49 interventional studies, 137 across the 16 observational. Of the 49 that completed or were terminated, 22 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 65 have an industry lead sponsor. The 10 most frequent:
Montefiore Medical Center is the lead sponsor of 416 studies on the registry; 68 are open to participants now.
Of its 89 completed or terminated interventional studies of FDA-regulated products, 77 (87%) have results posted.
Montefiore Medical Center has 2 studies filed under Bronchiolitis — fewer than ten, so there is no comparison to draw.
1 of the studies in Bronchiolitis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05443607Tulane UniversityTransplacental Transmission of RSV (TTRSV) | 2027-08 |
Add it to your calendar (.ics) → With an account.
Among the 65 studies in Bronchiolitis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This project aims to answer whether the use of a Neurally-Adjusted Ventilatory Assistance mode for non-invasive ventilation in pediatric patients with bronchiolitis results in improved comfort and reduced escalations in therapy (including intubation) when compared to using a standard mode of non-invasive ventilation. Neurally-Adjusted Ventilatory Assistance (NAVA) has been shown to result in greater synchrony then the standard mode of non-invasive ventilation. The study team hypothesizes that this improved synchrony can result in important clinical improvements when NAVA is used to treat children with bronchiolitis.
Bronchiolitis is a common diagnosis in pediatric hospitals and critical care units. Viral infection in younger patients often results in increased work of breathing, hypoxemia, impaired ventilation, and increased secretion burden. In some cases, treatment of severe respiratory failure includes intubation and mechanical ventilation. Current practice for patients with bronchiolitis who require hospital admission is to initially provide non-invasive ventilation to improve the patient's respiratory mechanics. This non-invasive respiratory support can range from simple nasal cannula, to high-flow nasal cannula, to non-invasive positive pressure ventilation.
The high-flow nasal cannula (HFNC) provides warm, humidified, oxygen-enriched air. Therapy commonly is prescribed with a prescribed fraction of inhaled oxygen (FiO2) delivered at 1-2 L/kg/min. This helps to improve oxygenation as the high rate of flow can "wash-out" carbon dioxide in the upper airways and thus reduce the volume of dead space ventilation.
Non-invasive ventilation (NIV) essentially provides a similar method of support as invasive ventilation without the use of endotracheal tube. Prescribed airway support is instead delivered non-invasively through a specialized nasal cannula or for larger children an occlusive facemask of appropriate size. The ventilator provides positive-end expiratory pressure (PEEP) with a prescribed delivery rate of a set inspiratory pressure (positive inspiratory pressure, or pressure control). This ventilator support enables the delivery of a set FiO2, helps maintain open airways to reduce atelectasis and allow for improved oxygenation with better V/Q matching, and improves work of breathing. The ventilator analyzes the flow generated by the patient's inspiratory effort and attempts to provide the prescribed positive inspiratory pressure at the time of the patient's own effort.
One of the major drawbacks of non-invasive ventilation for young pediatric patients with bronchiolitis is the difficulty in achieving synchrony between patient effort and ventilator-delivered positive inspiratory pressure. This is secondary to the large air leak given the non-invasive apparatus and the low inspiratory flows generated by this patient population. Thus, the ventilator and patient are often dyssynchronous which may actually increase work of breathing and agitation while impeding on the ventilatory support provided.
Neurally-Adjusted Ventilatory Assistance (NAVA) attempts to mitigate the harms of ventilator/patient dyssynchrony. This modality utilizes a specialized catheter placed into the esophagus, often via a nasogastric route, which has the capability of monitoring the electrical activity of the patient's diaphragm. This catheter can also be utilized to deliver feeds similarly to a basic nasogastric tube. The NAVA catheter monitors both the activation of the patient's diaphragm (indicating patient respiratory effort) and the strength of this activation in, referred to as the electrical activity of the diaphragm (Edi) and measured in millivolts (µV). Both human and animal studies have positively correlated the peak Edi values with work-of-breathing and demonstrated higher Edi values when respiratory pathology is present . Based on the Edi tracing, the ventilator can then deliver positive inspiratory pressure that is synchronous with both the patient's respiratory effort and proportional to the strength of this effort through a multiplier referred to as the NAVA level on the ventilator. This modality has been shown to improve patient agitation levels, reduce the need for sedating medications, and enhance synchrony in non-invasive ventilation modes.
The current practice model of the investigators entails that patients with bronchiolitis who require more than 1.5 L/kg of HFNC or require non-invasive ventilation, whether via a conventional or NAVA modality, are managed in the Pediatric Intensive Care Unit (PICU). Both modalities for non-invasive ventilation (conventional and NAVA) are used routinely. Patient respiratory status is aggregated into a value known as the Respiratory Severity Score (RSS) which accounts for respiratory rate, dyspnea, retractions, and auscultatory findings adjusted for the age of the patient. The RSS value is a validated assessment tool with good interobserver reliability between Medical Doctors (MDs), Registered Nurses (RNs), and Respiratory Therapists (RTs). It is calculated on a 4-hour basis for all patients with bronchiolitis in the investigator's PICU and helps determine clinical improvement or deterioration and better guide decisions to increase or decrease support.
While multiple physiologic studies demonstrate a reduced work of breathing with invasive NAVA ventilation, the majority of pediatric studies focused on non-invasive NAVA ventilation were designed to determine improvements in patient/ventilator synchronization. The investigators' project aims are two-fold. The study team hypothesizes that Edi levels and RSS scores will positively correlate for patients with bronchiolitis, allowing for another metric to gauge clinical status. The investigators also hypothesizes that the improved synchronization on NAVA-NIV may improve respiratory status as measured by RSS scores and Edi levels, reduce further escalations in respiratory support, shorten the length of non-invasive ventilation required, and reduce intubation rates. This improvement will be more substantial when transitioning from HFNC to NAVA-NIV compared to transitioning to conventional-NIV.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This arm will utilize a standard mode of non-invasive ventilation within protocol parameters.
Device: Standard Non-Invasive Mechanical Servo Ventilation
This arm with utilize a NAVA mode of non-invasive ventilation within protocol parameters.
Device: Neurally-Adjusted Ventilatory Assistance (NAVA) Non-Invasive Mechanical Servo Ventilation
The active comparator arm will utilize a standard non-invasive mode to provide ventilation support
The experimental arm will utilize a NAVA mode to provide non-invasive ventilation support
Baseline Respiratory Severity Score (RSS)
RSS is a validated measure of severity in children with bronchiolitis, scored from 0-12 with higher numbers indicating greater severity. If able, baseline scores will be taken before randomization to either treatment arm.
Time frame: Approximately one hour after Edi catheter placement
Average Respiratory Severity Score (RSS)
RSS is a validated measure of severity in children with bronchiolitis, scored from 0-12 with higher numbers indicating greater severity. Average RSS values over a 48-hour period will be reported for each treatment arm.
Time frame: 48 hour average, values collected at ~4 hour intervals.
Baseline Electrical Activity of the Diaphragm (Edi)
Measure, in microvolts, recorded by the Edi catheter to reflect activity of diaphragmatic activation. Higher values correspond with increased diaphragmatic activation. If able, will be collected prior to randomization to either treatment arm.
Time frame: Approximately one hour after Edi catheter placement
Average Baseline Electrical Activity of the Diaphragm (Edi)
Measure, in microvolts, recorded by the Edi catheter to reflect activity of diaphragmatic activation. Higher values correspond with increased diaphragmatic activation. Average Edi values over a 48-hour period will be reported for each treatment arm.
Time frame: 48 hour average, values collected at ~4 hour intervals.
Duration of Non-Invasive Ventilation
The duration, in hours, that a patient requires non-invasive ventilation.
Time frame: Time of randomization or start of non-invasive ventilation (whichever occurs last) up to 4 weeks later or time of intubation (whichever occurs first)
Number of participants requiring intubation
If a patient requires intubation due to bronchiolitis, this information will be recorded
Time frame: Following start of non-invasive ventilation or randomization (whichever comes last) up to 4 weeks later
Frequency of increasing ventilatory support
The number of times that a physician increases respiratory support settings on the ventilator (other than FiO2) while remaining within protocol parameters will be documented. The number of events, limited to one event per hour, of increase in respiratory support will be counted during the study period. A greater number of increases in ventilatory support will indicate inadequate response to the treatment arm intervention.
Time frame: From hours 4-48 of the intervention period
Number of patients requiring dexmedetomidine
The number of patients requiring dexmedetomidine will be tabulated. The use of dexmedetomidine use likely reflects patient agitation and inability to ventilate adequately on non-invasive ventilation. The use of dexmedetomidine may indicate more agitation present within a given treatment arm.
Time frame: Through 48 hour study intervention period
Plan to share: No
Ran from Dec 2023 to primary completion in May 2025, 17 months.
Primary completion moved twice since we started tracking on Sep 25, 2026: Mar 2027 → May 2025, last on Nov 13, 2026.
Completion moved twice since we started tracking on Sep 25, 2026: Mar 2027 → May 2025, last on Nov 13, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Challenges associated with accrual of the eligible patient population.
Challenges associated with accrual of the eligible patient population.
Study suspended pending outcome of discussions among IRB, PI, and DSMC
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.